GENPREX INC DL-,001

Genprex announced that an abstract on predictive biomarkers in patients receiving the Reqorsa gene therapy (Quaratusugen-Ozeplasmid) was accepted for the 2026 annual meeting of the American Society of Clinical Oncology (ASCO). The abstract includes clinical data intended to predict response to Reqorsa; Reqorsa is currently being evaluated in studies of non-small cell and small cell lung cancer and holds Fast-Track and orphan-drug status from the FDA. Financial context: Genprex has a market capitalization of about $9.86 million and is trading near its 52-week low. » Más en de.investing.com

The Australian patent office has accepted an application for use of the gene therapy REQORSA in combination with PD-L1 antibodies (including Tecentriq) for cancer treatment, strengthening Genprex’s intellectual property. The patent covers the combination being tested as maintenance therapy in the ongoing Acclaim-3 trial for advanced small-cell lung cancer; similar patents already exist in the US and Korea, and additional applications are pending worldwide. Genprex has added the University of Kentucky as an additional study site and plans to recruit the first 25 patients by H1 2026; an interim analysis of the phase‑2 data is expected in H2 2026. The study has FDA Fast Track and Orphan Drug designation; the phase‑1 portion showed good tolerability with no dose-limiting toxicities. » Más en de.investing.com

Genprex says proceeds from direct placements, an at‑the‑market program and an equity credit facility are expected to raise its equity above the Nasdaq Capital Market minimum requirement. The Nasdaq hearing panel has not yet made a final decision; an extension is in effect until December 31, 2025. Genprex also reports compliance with the minimum bid price requirement, Phase 1 data for Reqorsa in combination with Tagrisso showing no dose‑limiting toxicities, a prospectus supplement for an ATM offering of up to $75 million, as well as a U.S. patent and an intended EP patent grant for Reqorsa combinations. » Más en de.investing.com